Clinical research company Kendle has announced that it is now offering Brain Network Activation (BNA) imaging.
BNA imaging technology, developed by Israeli medical technology company ElMindA, directly observes the brain’s response to central nervous system medication and evaluates drug interactions.
It provides a non-invasive platform for mapping, monitoring and understanding brain network activity in response to cognitive or physiological stimuli.
The technology uses a set of signal processing and pattern recognition techniques to expose electrophysiological neural networks, combining the standard 64-electrode EEG with the spatial resolution of an fMRI.
Kendle hopes that BNA technology will speed up research in key areas like Alzheimer’s disease, mild cognitive impairment, schizophrenia, pain, ADHD, depression, anxiety, sleep disorders and narcolepsy.
It is suitable for SAD/MAD discovery, proof-of-concept and proof-of-mechanism studies, patient bridging and identifying select responder populations.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
BNA technology is currently available to Kendle customers through the company’s early stage units in Toronto, Canada, and Utrecht, The Netherlands.